MEP urges EMA to postpone adoption of data disclosure policy
This article was originally published in SRA
Just days before the European Medicines Agency's management board is due to adopt its new policy on the disclosure of clinical trial data, the MEP who steered the landmark Clinical Trials Regulation through the European Parliament has called on the agency to postpone its decision1.
You may also be interested in...
Roche plans to appeal against a penalty imposed by the Romanian competition authorities for implementing strategies that were said to delay the entry of competing biosimilar and generic products.
The EU association representing parallel traders says cheaper parallel imports are vital in keeping medicines affordable for member states.
The latest drug safety actions by the European Medicines Agency affect products for dermatological use and vaginal atrophy.